| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunologic Deficiency Syndromes | 17 | 2023 | 205 | 4.370 |
Why?
|
| Gain of Function Mutation | 11 | 2022 | 104 | 2.180 |
Why?
|
| Severe Combined Immunodeficiency | 9 | 2024 | 106 | 2.140 |
Why?
|
| STAT3 Transcription Factor | 7 | 2022 | 220 | 2.060 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 5 | 2022 | 145 | 1.990 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 15 | 2023 | 1199 | 1.580 |
Why?
|
| Killer Cells, Natural | 9 | 2022 | 327 | 1.510 |
Why?
|
| Immune System Diseases | 5 | 2025 | 46 | 1.450 |
Why?
|
| STAT1 Transcription Factor | 6 | 2021 | 73 | 1.270 |
Why?
|
| Pyrazoles | 5 | 2020 | 304 | 1.250 |
Why?
|
| Janus Kinase Inhibitors | 3 | 2024 | 22 | 1.240 |
Why?
|
| Granulomatous Disease, Chronic | 4 | 2020 | 66 | 1.150 |
Why?
|
| Janus Kinases | 6 | 2024 | 31 | 0.950 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2020 | 150 | 0.810 |
Why?
|
| STAT5 Transcription Factor | 3 | 2023 | 89 | 0.730 |
Why?
|
| STAT Transcription Factors | 3 | 2024 | 23 | 0.700 |
Why?
|
| Mutation | 15 | 2023 | 5825 | 0.690 |
Why?
|
| Knee | 1 | 2019 | 16 | 0.650 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2019 | 23 | 0.650 |
Why?
|
| Actin-Related Protein 2-3 Complex | 1 | 2019 | 11 | 0.630 |
Why?
|
| Pneumonia | 1 | 2022 | 323 | 0.610 |
Why?
|
| Edema | 1 | 2019 | 137 | 0.600 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 356 | 0.580 |
Why?
|
| Lymphoma | 1 | 2020 | 322 | 0.570 |
Why?
|
| Genetic Testing | 4 | 2022 | 1002 | 0.550 |
Why?
|
| Humans | 66 | 2025 | 124727 | 0.550 |
Why?
|
| Fever | 1 | 2019 | 296 | 0.540 |
Why?
|
| Cytokines | 5 | 2022 | 1290 | 0.540 |
Why?
|
| Wiskott-Aldrich Syndrome | 3 | 2023 | 23 | 0.530 |
Why?
|
| Autoimmune Diseases | 5 | 2023 | 251 | 0.530 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 505 | 0.520 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 883 | 0.490 |
Why?
|
| Child | 24 | 2025 | 24385 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2021 | 818 | 0.480 |
Why?
|
| Child, Preschool | 19 | 2025 | 14017 | 0.470 |
Why?
|
| Infant | 15 | 2025 | 12475 | 0.440 |
Why?
|
| Joint Diseases | 1 | 2023 | 33 | 0.420 |
Why?
|
| Transcription Factors | 1 | 2022 | 2580 | 0.400 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 30 | 0.390 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2025 | 3154 | 0.370 |
Why?
|
| Adolescent | 18 | 2025 | 19288 | 0.370 |
Why?
|
| Genome, Human | 1 | 2018 | 1273 | 0.360 |
Why?
|
| Multifactorial Inheritance | 2 | 2025 | 139 | 0.360 |
Why?
|
| Colitis, Ulcerative | 1 | 2023 | 205 | 0.350 |
Why?
|
| Lymphopenia | 2 | 2024 | 36 | 0.350 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 2043 | 0.340 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1758 | 0.340 |
Why?
|
| Crohn Disease | 1 | 2023 | 283 | 0.330 |
Why?
|
| Agammaglobulinemia | 2 | 2022 | 40 | 0.320 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2021 | 225 | 0.320 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 542 | 0.310 |
Why?
|
| Male | 23 | 2025 | 61270 | 0.300 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2023 | 336 | 0.300 |
Why?
|
| Rheumatic Diseases | 1 | 2019 | 70 | 0.300 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2025 | 304 | 0.290 |
Why?
|
| Autoimmunity | 3 | 2022 | 172 | 0.290 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2017 | 28 | 0.270 |
Why?
|
| Herpesvirus 4, Human | 2 | 2021 | 676 | 0.270 |
Why?
|
| Sepsis | 2 | 2021 | 478 | 0.270 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2017 | 49 | 0.260 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 270 | 0.260 |
Why?
|
| Sirolimus | 1 | 2018 | 226 | 0.260 |
Why?
|
| Th17 Cells | 1 | 2017 | 91 | 0.260 |
Why?
|
| Coatomer Protein | 1 | 2016 | 30 | 0.260 |
Why?
|
| Female | 25 | 2025 | 66569 | 0.250 |
Why?
|
| Th1 Cells | 1 | 2017 | 153 | 0.250 |
Why?
|
| Tuberculosis | 1 | 2022 | 521 | 0.250 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 219 | 0.250 |
Why?
|
| Myosin Type V | 1 | 2025 | 9 | 0.240 |
Why?
|
| Immunophenotyping | 3 | 2018 | 330 | 0.240 |
Why?
|
| Immunological Synapses | 2 | 2019 | 26 | 0.240 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2020 | 263 | 0.230 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2018 | 294 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 529 | 0.230 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 2 | 2023 | 10 | 0.230 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2022 | 176 | 0.220 |
Why?
|
| Phospholipase C gamma | 1 | 2023 | 19 | 0.220 |
Why?
|
| Nitriles | 4 | 2020 | 146 | 0.220 |
Why?
|
| Mutation, Missense | 2 | 2020 | 875 | 0.220 |
Why?
|
| Eczema | 1 | 2023 | 29 | 0.220 |
Why?
|
| Infant, Newborn | 8 | 2024 | 8191 | 0.210 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2023 | 25 | 0.210 |
Why?
|
| Transplantation Conditioning | 3 | 2023 | 324 | 0.210 |
Why?
|
| Adult | 14 | 2023 | 29489 | 0.200 |
Why?
|
| Leukopenia | 1 | 2023 | 44 | 0.200 |
Why?
|
| Primary Myelofibrosis | 1 | 2023 | 51 | 0.200 |
Why?
|
| Signal Transduction | 3 | 2024 | 4493 | 0.200 |
Why?
|
| Young Adult | 9 | 2021 | 9025 | 0.190 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 54 | 0.190 |
Why?
|
| UDPglucose 4-Epimerase | 1 | 2021 | 7 | 0.190 |
Why?
|
| Galactosemias | 1 | 2021 | 14 | 0.190 |
Why?
|
| Pyrimidines | 4 | 2020 | 367 | 0.190 |
Why?
|
| Age of Onset | 3 | 2025 | 590 | 0.180 |
Why?
|
| Cell Proliferation | 3 | 2024 | 2285 | 0.180 |
Why?
|
| Cohort Studies | 2 | 2022 | 4804 | 0.180 |
Why?
|
| Lymphocytes | 1 | 2022 | 406 | 0.180 |
Why?
|
| Patient Care Team | 1 | 2025 | 541 | 0.180 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2021 | 46 | 0.180 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 1707 | 0.180 |
Why?
|
| Membrane Proteins | 2 | 2020 | 1532 | 0.180 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2020 | 18 | 0.170 |
Why?
|
| France | 1 | 2020 | 80 | 0.170 |
Why?
|
| Laboratories | 1 | 2021 | 82 | 0.170 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 29 | 0.170 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2020 | 28 | 0.170 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 192 | 0.170 |
Why?
|
| Mycobacterium avium Complex | 1 | 2019 | 17 | 0.160 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 152 | 0.160 |
Why?
|
| Heterozygote | 3 | 2018 | 671 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 155 | 0.160 |
Why?
|
| Immunologic Memory | 1 | 2020 | 187 | 0.160 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 205 | 0.150 |
Why?
|
| Thymus Gland | 2 | 2023 | 101 | 0.150 |
Why?
|
| Homozygote | 1 | 2020 | 548 | 0.150 |
Why?
|
| Actins | 1 | 2020 | 341 | 0.150 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2018 | 29 | 0.150 |
Why?
|
| Candidiasis, Chronic Mucocutaneous | 2 | 2018 | 5 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 217 | 0.150 |
Why?
|
| Alemtuzumab | 1 | 2018 | 88 | 0.140 |
Why?
|
| Inflammation | 3 | 2021 | 1431 | 0.140 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2017 | 64 | 0.140 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 533 | 0.140 |
Why?
|
| Molecular Chaperones | 1 | 2018 | 167 | 0.140 |
Why?
|
| Arthritis | 2 | 2019 | 80 | 0.140 |
Why?
|
| Phenotype | 4 | 2023 | 4255 | 0.130 |
Why?
|
| Neonatal Screening | 3 | 2024 | 184 | 0.130 |
Why?
|
| Hypersensitivity | 1 | 2019 | 183 | 0.130 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 161 | 0.130 |
Why?
|
| rab27 GTP-Binding Proteins | 1 | 2016 | 5 | 0.130 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 58 | 0.130 |
Why?
|
| Interferon Type I | 2 | 2021 | 107 | 0.130 |
Why?
|
| Diarrhea | 1 | 2017 | 317 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 74 | 0.120 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 144 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 354 | 0.120 |
Why?
|
| Pedigree | 3 | 2020 | 1605 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 1265 | 0.110 |
Why?
|
| Lung Diseases | 2 | 2019 | 383 | 0.110 |
Why?
|
| Fontan Procedure | 1 | 2016 | 182 | 0.110 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2023 | 22 | 0.110 |
Why?
|
| Animals | 5 | 2022 | 34027 | 0.100 |
Why?
|
| Cell Differentiation | 2 | 2022 | 1883 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 540 | 0.100 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2022 | 15 | 0.100 |
Why?
|
| I-kappa B Kinase | 1 | 2022 | 61 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2023 | 182 | 0.100 |
Why?
|
| Genetic Therapy | 2 | 2023 | 679 | 0.100 |
Why?
|
| Texas | 1 | 2020 | 3586 | 0.100 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 778 | 0.090 |
Why?
|
| BCG Vaccine | 1 | 2022 | 109 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2023 | 249 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 949 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1684 | 0.090 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 281 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2016 | 1497 | 0.080 |
Why?
|
| Survival Rate | 3 | 2020 | 2047 | 0.080 |
Why?
|
| Disease Management | 2 | 2025 | 524 | 0.080 |
Why?
|
| Unrelated Donors | 2 | 2020 | 82 | 0.080 |
Why?
|
| Contracture | 1 | 2019 | 24 | 0.080 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 39 | 0.080 |
Why?
|
| Incidence | 3 | 2023 | 3142 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2022 | 472 | 0.080 |
Why?
|
| RNA | 1 | 2022 | 570 | 0.080 |
Why?
|
| Facies | 1 | 2019 | 153 | 0.080 |
Why?
|
| Mice | 2 | 2022 | 17578 | 0.080 |
Why?
|
| Immunoglobulins | 1 | 2019 | 171 | 0.080 |
Why?
|
| Genomics | 1 | 2016 | 1501 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2023 | 16334 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2019 | 77 | 0.070 |
Why?
|
| Intestinal Diseases | 1 | 2019 | 83 | 0.070 |
Why?
|
| Homeostasis | 1 | 2022 | 679 | 0.070 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 208 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2428 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2023 | 1614 | 0.070 |
Why?
|
| Viremia | 1 | 2018 | 127 | 0.070 |
Why?
|
| Growth Disorders | 1 | 2019 | 209 | 0.070 |
Why?
|
| Amino Acid Substitution | 2 | 2020 | 393 | 0.070 |
Why?
|
| Allografts | 2 | 2017 | 191 | 0.070 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 332 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 287 | 0.070 |
Why?
|
| Prognosis | 3 | 2020 | 4627 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 348 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 354 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 793 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2019 | 375 | 0.060 |
Why?
|
| Microcephaly | 1 | 2019 | 330 | 0.060 |
Why?
|
| Precision Medicine | 1 | 2019 | 319 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 873 | 0.060 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 691 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 777 | 0.060 |
Why?
|
| Middle Aged | 4 | 2020 | 26797 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 336 | 0.060 |
Why?
|
| Pituitary Gland | 1 | 1995 | 82 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 5161 | 0.060 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 1815 | 0.060 |
Why?
|
| Pituitary Neoplasms | 1 | 1995 | 80 | 0.060 |
Why?
|
| Cell Line | 2 | 2020 | 2746 | 0.060 |
Why?
|
| Adenoma | 1 | 1995 | 129 | 0.050 |
Why?
|
| Meningioma | 1 | 1995 | 120 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2023 | 53 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1018 | 0.050 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 960 | 0.050 |
Why?
|
| Canada | 1 | 2023 | 287 | 0.050 |
Why?
|
| Aged | 3 | 2016 | 19764 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2020 | 12357 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2022 | 74 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3038 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2023 | 235 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2016 | 481 | 0.050 |
Why?
|
| Glycolipids | 1 | 2021 | 32 | 0.050 |
Why?
|
| Intellectual Disability | 1 | 2019 | 1056 | 0.050 |
Why?
|
| Wiskott-Aldrich Syndrome Protein Family | 1 | 2020 | 7 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 38 | 0.040 |
Why?
|
| ADP-Ribosylation Factor 1 | 1 | 2020 | 7 | 0.040 |
Why?
|
| Cytidine Deaminase | 1 | 2020 | 31 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2092 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2021 | 140 | 0.040 |
Why?
|
| Myeloablative Agonists | 1 | 2020 | 25 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 191 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 3716 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 243 | 0.040 |
Why?
|
| Transplantation Chimera | 1 | 2019 | 37 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2022 | 543 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1356 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 119 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1328 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2023 | 536 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 502 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 482 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 250 | 0.040 |
Why?
|
| Motivation | 1 | 2021 | 316 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 298 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 186 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 266 | 0.040 |
Why?
|
| Calcium | 1 | 2023 | 1099 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 28 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 28 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 61 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2018 | 41 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 317 | 0.040 |
Why?
|
| Mutant Proteins | 1 | 2018 | 115 | 0.040 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2017 | 6 | 0.040 |
Why?
|
| CD56 Antigen | 1 | 2017 | 26 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 662 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2018 | 120 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2018 | 180 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2018 | 262 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 381 | 0.030 |
Why?
|
| Pyrroles | 1 | 2018 | 177 | 0.030 |
Why?
|
| Piperidines | 1 | 2018 | 204 | 0.030 |
Why?
|
| Registries | 1 | 2023 | 1434 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1233 | 0.030 |
Why?
|
| Piebaldism | 1 | 2016 | 3 | 0.030 |
Why?
|
| Albinism | 1 | 2016 | 8 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 399 | 0.030 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2016 | 19 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 325 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1883 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2634 | 0.030 |
Why?
|
| Consanguinity | 1 | 2016 | 116 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 1995 | 1212 | 0.030 |
Why?
|
| Exons | 1 | 2018 | 796 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2016 | 147 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 1119 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2016 | 185 | 0.030 |
Why?
|
| Family | 1 | 2018 | 563 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 797 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2016 | 172 | 0.030 |
Why?
|
| Base Sequence | 1 | 2018 | 3090 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 336 | 0.030 |
Why?
|
| Brain | 1 | 1995 | 2982 | 0.030 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2016 | 342 | 0.030 |
Why?
|
| Risk Factors | 2 | 2017 | 10286 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 468 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1736 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2022 | 6147 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2814 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 3717 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 2895 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 2820 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 1151 | 0.020 |
Why?
|
| Prolactin | 1 | 1995 | 113 | 0.010 |
Why?
|
| Radiography | 1 | 1995 | 821 | 0.010 |
Why?
|
| Sex Factors | 1 | 1995 | 1287 | 0.010 |
Why?
|